In relation to cancer drug therapy and SOCS3’s role as a suppressor of STAT3 activation, there has already been evidence shown in inhibiting growth of non-small lung cancer cells as well as overexpression of SOCS3 limiting the growth of malignant fibrous histiocytoma through inhibition of STAT3 and IL-6 production. This evidence concerns the gene SOCS3 and undifferentiated pleomorphic sarcoma.